RU97112089A - SOLID PHARMACEUTICAL COMPOSITION WITH REGULATED MEDICINAL RELEASE - Google Patents

SOLID PHARMACEUTICAL COMPOSITION WITH REGULATED MEDICINAL RELEASE

Info

Publication number
RU97112089A
RU97112089A RU97112089/14A RU97112089A RU97112089A RU 97112089 A RU97112089 A RU 97112089A RU 97112089/14 A RU97112089/14 A RU 97112089/14A RU 97112089 A RU97112089 A RU 97112089A RU 97112089 A RU97112089 A RU 97112089A
Authority
RU
Russia
Prior art keywords
composition according
acid
alginate
sodium alginate
drug
Prior art date
Application number
RU97112089/14A
Other languages
Russian (ru)
Other versions
RU2142793C1 (en
Inventor
Невил У. Борд
Элан Ф. Кармоди
Брайен К. Уизерз
Лайэм К. Фили
Original Assignee
Абботт Лаборэтриз
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from US08/574,877 external-priority patent/US5705190A/en
Application filed by Абботт Лаборэтриз filed Critical Абботт Лаборэтриз
Publication of RU97112089A publication Critical patent/RU97112089A/en
Application granted granted Critical
Publication of RU2142793C1 publication Critical patent/RU2142793C1/en

Links

Claims (19)

1. Твердая фармацевтическая композиция с регулируемым высвобождением лекарственного средства для орального употребления, включающая терапевтически эффективное количество по крайней мере одного основного лекарственного средства, имеющего растворимость в воде менее, чем 1 ч. на 30 ч. воды, водорастворимую альгинатную соль, комплексную соль альгиновой кислоты и эффективное количество органической карбоксильной кислоты для облегчения растворения основного лекарства.1. Solid pharmaceutical composition with controlled release of the medicinal product for oral use, comprising a therapeutically effective amount of at least one basic drug having a solubility in water of less than 1 part per 30 parts of water, a water-soluble alginate salt, a complex salt of alginic acid and an effective amount of an organic carboxylic acid to facilitate dissolution of the main drug. 2. Композиция по п. 1, отличающаяся тем, что она имеет форму таблетки. 2. The composition according to p. 1, characterized in that it has the form of a tablet. 3. Композиция по п. 1, отличающаяся тем, что она имеет форму препарата для схемы приема лекарственного средства один раз в день. 3. The composition according to p. 1, characterized in that it has the form of a drug for the regimen of taking the drug once a day. 4. Композиция по п. 1, отличающаяся тем, что она содержит в качестве основного лекарственного средства макролид. 4. The composition according to p. 1, characterized in that it contains macrolide as the main drug. 5. Композиция по п. 4, отличающаяся тем, что макролидом является кларитромицин. 5. The composition according to p. 4, characterized in that the macrolide is clarithromycin. 6. Композиция по п. 1, отличающаяся тем, что она содержит в качестве водорастворимой альгинатной соли альгинат натрия. 6. The composition according to p. 1, characterized in that it contains sodium alginate as a water-soluble alginate salt. 7. Композиция по п. 1, отличающаяся тем, что она содержит в качестве комплексной соли альгиновой кислоты альгинат натрия-кальция. 7. The composition according to claim 1, characterized in that it contains sodium-calcium alginate as a complex salt of alginic acid. 8. Композиция по п. 1, отличающаяся тем, что она содержит в качестве органической карбоновой кислоты соединение, выбранное из группы, включающей винную кислоту, яблочную кислоту, янтарную кислоту, глутаровую кислоту, глютаминовую кислоту, малеиновую кислоту, миндальную кислоту и лимонную кислоту. 8. The composition according to p. 1, characterized in that it contains as an organic carboxylic acid a compound selected from the group consisting of tartaric acid, malic acid, succinic acid, glutaric acid, glutamic acid, maleic acid, mandelic acid and citric acid. 9. Композиция по п. 8, отличающаяся тем, что в качестве органической карбоновой кислоты она содержит лимонную кислоту. 9. The composition according to claim 8, characterized in that it contains citric acid as an organic carboxylic acid. 10. Композиция по п. 1, отличающаяся тем, что она содержит водорастворимую альгинатную соль и комплексную соль альгиновой кислоты при их массовом соотношении соответственно от 16: 1 до 1: 1. 10. The composition according to p. 1, characterized in that it contains a water-soluble alginate salt and a complex salt of alginic acid in their mass ratio, respectively, from 16: 1 to 1: 1. 11. Композиция по п. 10, отличающаяся тем, что она содержит альгинат натрия и альгинат натрия-кальция, при их массовом соотношении соответственно от 16: 1 до 1: 1. 11. The composition according to p. 10, characterized in that it contains sodium alginate and sodium alginate-calcium, with their mass ratio, respectively, from 16: 1 to 1: 1. 12. Композиция по п. 11, отличающаяся тем, что она содержит альгинат натрия и альгинат натрия-кальция при их массовом соотношении соответственно от 8: 1 до 2: 1. 12. The composition according to p. 11, characterized in that it contains sodium alginate and sodium calcium alginate in a weight ratio of 8: 1 to 2: 1, respectively. 13. Композиция по п. 1, отличающаяся тем, что она содержит органическую карбоновую кислоту и основное лекарственное средство при их молярном соотношении соответственно от 0,2: 1 до 5: 1. 13. The composition according to p. 1, characterized in that it contains an organic carboxylic acid and the main drug in their molar ratio, respectively, from 0.2: 1 to 5: 1. 14. Композиция по п. 1, отличающаяся тем, что она содержит органическую карбоновую кислоту и основное лекарственное средство при их молярном соотношении 1: 1. 14. The composition according to p. 1, characterized in that it contains organic carboxylic acid and the main drug in their molar ratio of 1: 1. 15. Композиция по п. 1, отличающаяся тем, что она содержит основное лекарственное средство, выбранное из группы, включающей сульфометоксазол, метронидазол, циметидин, индапаамид, атенолол диазепам. 15. The composition according to p. 1, characterized in that it contains the main drug selected from the group comprising sulfomethoxazole, metronidazole, cimetidine, indapamide, atenolol diazepam. 16. Композиция по п. 4, отличающаяся тем, что она содержит макролид, выбранный из группы, включающей эритромицин, диритромицин, азитромицин, рокситромицин и АВТ-229. 16. The composition according to p. 4, characterized in that it contains a macrolide selected from the group consisting of erythromycin, dirithromycin, azithromycin, roxithromycin and ABT-229. 17. Композиция для орального употребления лекарственного средства по схеме приема один раз в день по п. 1, отличающаяся тем, что она включает в себя 500 мг кларитромицина, 75 - 400 мг альгината натрия 10 - 400 мг альгината натрия-кальция и 128 мг лимонной кислоты. 17. The composition for oral administration of the drug according to the once-daily regimen according to claim 1, characterized in that it includes 500 mg of clarithromycin, 75 to 400 mg of sodium alginate, 10 to 400 mg of sodium calcium alginate and 128 mg of lemon acids. 18. Композиция по п. 17, отличающаяся тем, что она включает 80 - 200 мг альгината натрия и 10 - 40 мг альгината натрия-кальция. 18. The composition according to p. 17, characterized in that it comprises 80 to 200 mg of sodium alginate and 10 to 40 mg of sodium alginate calcium. 19. Композиция по п. 18, отличающаяся тем, что она включает 120 мг альгината натрия и 15 мг альгината натрия-кальция. 19. The composition according to p. 18, characterized in that it comprises 120 mg of sodium alginate and 15 mg of sodium alginate calcium.
RU97112089A 1995-12-19 1996-11-25 Controlled-release drug solid pharmaceutical composition RU2142793C1 (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US08/574,877 US5705190A (en) 1995-12-19 1995-12-19 Controlled release formulation for poorly soluble basic drugs
US08/574,877 1995-12-19
PCT/US1996/018960 WO1997022335A1 (en) 1995-12-19 1996-11-25 A controlled release formulation for poorly soluble basic drugs

Publications (2)

Publication Number Publication Date
RU97112089A true RU97112089A (en) 1999-06-10
RU2142793C1 RU2142793C1 (en) 1999-12-20

Family

ID=24298013

Family Applications (1)

Application Number Title Priority Date Filing Date
RU97112089A RU2142793C1 (en) 1995-12-19 1996-11-25 Controlled-release drug solid pharmaceutical composition

Country Status (27)

Country Link
US (1) US5705190A (en)
EP (1) EP0799028B1 (en)
JP (1) JP3292732B2 (en)
KR (1) KR100632187B1 (en)
CN (1) CN1131027C (en)
AR (1) AR004391A1 (en)
AT (2) ATE170744T1 (en)
AU (1) AU701268B2 (en)
CA (1) CA2209714C (en)
CZ (1) CZ289158B6 (en)
DE (2) DE29624506U1 (en)
DK (1) DK0799028T3 (en)
ES (1) ES2122810T3 (en)
HK (1) HK1016873A1 (en)
HU (1) HUP9800516A3 (en)
IL (1) IL121275A (en)
IT (1) ITMI20050383U1 (en)
NZ (1) NZ323332A (en)
PL (1) PL186696B1 (en)
PT (1) PT103379B (en)
RO (1) RO117501B1 (en)
RU (1) RU2142793C1 (en)
TR (1) TR199800777T2 (en)
TW (1) TW429154B (en)
UA (1) UA40663C2 (en)
WO (1) WO1997022335A1 (en)
ZA (1) ZA9610110B (en)

Families Citing this family (100)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DK0758244T4 (en) * 1994-05-06 2008-06-16 Pfizer Controlled-release azithromycin dosage forms
TW487582B (en) * 1995-08-11 2002-05-21 Nissan Chemical Ind Ltd Method for converting sparingly water-soluble medical substance to amorphous state
WO1998056357A1 (en) * 1995-12-19 1998-12-17 Abbott Laboratories A controlled release formulation for poorly soluble basic drugs
US6551616B1 (en) * 1997-04-11 2003-04-22 Abbott Laboratories Extended release formulations of erythromycin derivatives
US6010718A (en) * 1997-04-11 2000-01-04 Abbott Laboratories Extended release formulations of erythromycin derivatives
US20050064033A1 (en) * 1997-04-11 2005-03-24 Notario Gerard F. Extended release formulations of erythromycin derivatives
US6156771A (en) * 1997-08-28 2000-12-05 Rubin; Walter Method for alleviation of lower gastrointestinal disorders in a human patient
RU2214244C9 (en) * 1998-03-26 2020-07-29 Астеллас Фарма Инк. Sustained-release preparations
IL141236A0 (en) * 1998-08-21 2002-03-10 Novartis Ag New oral formulations for 5-ht4 agonists or antagonists
IT1313610B1 (en) * 1999-08-09 2002-09-09 S I F I Societa Ind Farmaceuti PROCESS FOR THE PREPARATION OF AQUEOUS FORMULATIONS FOR OPHTHALMIC USE
TR200000054A2 (en) * 2000-01-05 2001-08-21 Sanovel İlaç San. Ve Ti̇c. Anoni̇m Şi̇rketi̇ Sustained-release tablet formulations containing clarithromycin.
US6544555B2 (en) * 2000-02-24 2003-04-08 Advancis Pharmaceutical Corp. Antibiotic product, use and formulation thereof
US6565882B2 (en) * 2000-02-24 2003-05-20 Advancis Pharmaceutical Corp Antibiotic composition with inhibitor
WO2001064224A1 (en) * 2000-02-29 2001-09-07 Teva Pharmaceutical Industries Ltd. Processes for preparing clarithromycin and clarithromycin intermediate, essentially oxime-free clarithromycin, and pharmaceutical composition comprising the same
KR20030011797A (en) * 2000-03-28 2003-02-11 바이오케미 게젤샤프트 엠베하 Granulated particles with masked taste
DE10031043A1 (en) * 2000-06-26 2002-02-14 Bayer Ag Retarded preparations of quinolone antibiotics and process for their preparation
IN192748B (en) * 2000-08-29 2004-05-15 Ranbaxy Lab Ltd
US6541014B2 (en) * 2000-10-13 2003-04-01 Advancis Pharmaceutical Corp. Antiviral product, use and formulation thereof
US20020068078A1 (en) * 2000-10-13 2002-06-06 Rudnic Edward M. Antifungal product, use and formulation thereof
US20020197314A1 (en) * 2001-02-23 2002-12-26 Rudnic Edward M. Anti-fungal composition
WO2003017981A1 (en) 2001-08-29 2003-03-06 Ranbaxy Laboratories Limited Controlled release formulation of clarithromycin or tinidazol
BR0212259A (en) * 2001-08-29 2004-10-19 Ranbaxy Lab Ltd Controlled release formulation of clarithromycin or tinidazole
US6642276B2 (en) * 2001-10-01 2003-11-04 M/S Ind-Swift Limited Controlled release macrolide pharmaceutical formulations
US20030091627A1 (en) * 2001-10-31 2003-05-15 Vinay Sharma Rate-controlled delivery of macrolides
CA2465405A1 (en) * 2001-11-02 2003-05-08 Wockhardt Limited Controlled release compositions for macrolide antimicrobial agents
US20030181488A1 (en) * 2002-03-07 2003-09-25 Boehringer Ingelheim Pharma Gmbh & Co. Kg Administration form for the oral application of 3-[(2-{[4-(hexyloxycarbonylamino-imino-methyl)-phenylamino]-methyl}-1-methyl-1H-benzimidazol-5-carbonyl)-pyridin-2-yl-amino]-propionic acid ethyl ester and the salts thereof
AU2003225837B2 (en) * 2002-03-15 2008-11-06 Forest Laboratories Holdings Limited NE and 5-HT reuptake inhibitors for treating visceral pain syndromes
AU2003245504A1 (en) * 2002-06-14 2003-12-31 Andrx Corporation Pharmaceutical compositions for drugs having ph-dependentsolubility
US20060083759A1 (en) * 2002-07-17 2006-04-20 Aleksander Resman Stabilization of the profile of release of active substances from a formulation
SI21300A (en) * 2002-10-08 2004-04-30 Krka, Tovarna Zdravil, D.D., Novo Mesto Pharmaceutical compositions with alginates
US20060003004A1 (en) * 2002-10-25 2006-01-05 Collegium Pharmaceutical, Inc. Pulsatile release compositions of milnacipran
US20040132826A1 (en) * 2002-10-25 2004-07-08 Collegium Pharmaceutical, Inc. Modified release compositions of milnacipran
GB0230034D0 (en) * 2002-12-23 2003-01-29 Biochemie Gmbh Organic compounds
JP2006515008A (en) * 2003-01-28 2006-05-18 コレギウム ファーマシューティカル， インコーポレイテッド Multiparticulate composition of milnacipran for oral administration
US20040185097A1 (en) * 2003-01-31 2004-09-23 Glenmark Pharmaceuticals Ltd. Controlled release modifying complex and pharmaceutical compositions thereof
EP1620111A4 (en) * 2003-05-06 2012-03-21 Nirmal Mulye Controlled release formulation of erythromycin derivatives
US7063862B2 (en) * 2003-06-03 2006-06-20 Biokey, Inc. Pharmaceutical composition and method for treating
PL1638529T3 (en) * 2003-06-16 2017-03-31 Andrx Pharmaceuticals, Llc. Oral extended-release composition
US20050053658A1 (en) * 2003-09-09 2005-03-10 Venkatesh Gopi M. Extended release systems for macrolide antibiotics
CA2533292C (en) * 2003-07-21 2013-12-31 Advancis Pharmaceutical Corporation Antibiotic product, use and formulation thereof
AU2004258944B2 (en) * 2003-07-21 2011-02-10 Shionogi, Inc. Antibiotic product, use and formulation thereof
AU2004258949B2 (en) * 2003-07-21 2011-02-10 Shionogi, Inc. Antibiotic product, use and formulation thereof
JP2007502296A (en) * 2003-08-11 2007-02-08 アドバンシス ファーマスーティカル コーポレイション Robust pellet
US8062672B2 (en) * 2003-08-12 2011-11-22 Shionogi Inc. Antibiotic product, use and formulation thereof
WO2005023184A2 (en) * 2003-08-29 2005-03-17 Advancis Pharmaceuticals Corporation Antibiotic product, use and formulation thereof
WO2005027877A1 (en) * 2003-09-15 2005-03-31 Advancis Pharmaceutical Corporation Antibiotic product, use and formulation thereof
WO2005030257A2 (en) * 2003-09-30 2005-04-07 Solubest Ltd. Water soluble nanoparticles inclusion complexes
WO2005053652A1 (en) 2003-12-04 2005-06-16 Pfizer Products Inc. Multiparticulate crystalline drug compositions containing a poloxamer and a glyceride
EP1694304A2 (en) * 2003-12-04 2006-08-30 Pfizer Products Inc. Azithromycin multiparticulate dosage forms by liquid-based processes
JP2007513143A (en) * 2003-12-04 2007-05-24 ファイザー・プロダクツ・インク Spray coagulation process for producing multiparticulate azithromycin compositions preferably using poloxamer and glycerides using an extruder
BRPI0417348A (en) * 2003-12-04 2007-03-13 Pfizer Prod Inc spray gelatinization process using an extruder for preparing multiparticulate crystalline drug compositions preferably containing a poloxamer and a glyceride
EP1691786A1 (en) * 2003-12-04 2006-08-23 Pfizer Products Inc. Multiparticulate compositions with improved stability
US6984403B2 (en) * 2003-12-04 2006-01-10 Pfizer Inc. Azithromycin dosage forms with reduced side effects
SI1691787T1 (en) * 2003-12-04 2008-10-31 Pfizer Prod Inc Method for making pharmaceutical multiparticulates
WO2005053639A2 (en) * 2003-12-04 2005-06-16 Pfizer Products Inc. Controlled release multiparticulates formed with dissolution enhancers
EP1701705A4 (en) * 2003-12-24 2007-08-08 Advancis Pharmaceutical Corp Enhanced absorption of modified release dosage forms
CN100435847C (en) * 2004-05-13 2008-11-26 宝龄富锦生技股份有限公司 Continuing release recipe of containing infusible basic remedy
US20050260263A1 (en) * 2004-05-18 2005-11-24 Panion & Bf Biotech Inc. Sustained release formulation for sparingly soluble main drugs
WO2006004795A2 (en) 2004-06-25 2006-01-12 The Johns Hopkins University Angiogenesis inhibitors
WO2006014427A1 (en) * 2004-07-02 2006-02-09 Advancis Pharmaceutical Corporation Tablet for pulsed delivery
CN1322866C (en) * 2004-10-12 2007-06-27 广州贝氏药业有限公司 Multi-unit slow-release preparation
DE102005042875A1 (en) * 2004-12-23 2006-09-21 Grünenthal GmbH Fast-release dosage forms for antibiotics
JP2009500356A (en) * 2005-07-07 2009-01-08 エラン ファーマ インターナショナル リミテッド Nanoparticulate clarithromycin formulation
US20070128272A1 (en) * 2005-12-07 2007-06-07 Zerbe Horst G Multi-vitamin and mineral supplement
US8357394B2 (en) 2005-12-08 2013-01-22 Shionogi Inc. Compositions and methods for improved efficacy of penicillin-type antibiotics
US8778924B2 (en) 2006-12-04 2014-07-15 Shionogi Inc. Modified release amoxicillin products
NZ570039A (en) * 2006-01-27 2011-07-29 Eurand Inc Drug delivery systems comprising weakly basic selective serotonin 5-HT3 blocking agent and organic acids
CN101410093A (en) * 2006-01-27 2009-04-15 欧兰德股份有限公司 Drug delivery systems comprising weakly basic drugs and organic acids
US8299052B2 (en) 2006-05-05 2012-10-30 Shionogi Inc. Pharmaceutical compositions and methods for improved bacterial eradication
EP2030613A1 (en) * 2007-08-17 2009-03-04 Abbott GmbH & Co. KG Preparation of compositions with essentially noncrystalline embedded macrolide antibiotics
KR101561571B1 (en) * 2007-12-28 2015-10-19 아지엔드 키미쉐 리유나이트 안젤리니 프란체스코 에이.씨.알.에이.에프. 에스.피.에이 A slow-release formulation based on an association of glycogen and alginate
US8133506B2 (en) * 2008-03-12 2012-03-13 Aptalis Pharmatech, Inc. Drug delivery systems comprising weakly basic drugs and organic acids
CN102239149B (en) 2008-10-06 2015-05-13 约翰·霍普金斯大学 Quinoline compounds as inhibitors of angiogenesis, human methionine aminopeptidase, and sirt1, and methods of treating disorders
CN102448834B (en) * 2009-05-29 2013-11-20 利乐拉瓦尔集团及财务有限公司 Packaging material comprising magnetisable portions
US20110003005A1 (en) * 2009-07-06 2011-01-06 Gopi Venkatesh Methods of Treating PDNV and PONV with Extended Release Ondansetron Compositions
WO2011005250A1 (en) * 2009-07-07 2011-01-13 Sepracor Inc. Formulations of 6- (5-chloro-2-pyridyl) - 5- [ (4-methyl-1-piperazinyl) carbonyloxy] - 7-0x0-6, 7- dihydro- 5h- phyrrolo [3, 4-b] pyrazine
EP2283824B1 (en) 2009-07-30 2017-04-19 Special Products Line S.p.A. Compositions and formulations based on swellable matrices for sustained release of poorly soluble drugs such as clarithromycin
CA2773037A1 (en) * 2009-09-02 2011-03-10 Bernard Charles Sherman Clarithromycin extended-release tablet
CN102106807B (en) 2009-12-29 2013-03-27 上海中西制药有限公司 Method for preparing solid preparation and solid preparation
US9011912B2 (en) 2010-10-07 2015-04-21 Abon Pharmaceuticals, Llc Extended-release oral dosage forms for poorly soluble amine drugs
US20140018404A1 (en) 2010-12-16 2014-01-16 Celgene Corporation Controlled release oral dosage forms of poorly soluble drugs and uses thereof
US9532977B2 (en) 2010-12-16 2017-01-03 Celgene Corporation Controlled release oral dosage forms of poorly soluble drugs and uses thereof
DE102013202703B4 (en) 2013-02-20 2020-03-12 Siemens Healthcare Gmbh Device and method for collision detection in a medical device
KR20210156320A (en) 2013-04-07 2021-12-24 더 브로드 인스티튜트, 인코퍼레이티드 Compositions and methods for personalized neoplasia vaccines
WO2015077717A1 (en) 2013-11-25 2015-05-28 The Broad Institute Inc. Compositions and methods for diagnosing, evaluating and treating cancer by means of the dna methylation status
US11725237B2 (en) 2013-12-05 2023-08-15 The Broad Institute Inc. Polymorphic gene typing and somatic change detection using sequencing data
AU2014368898B2 (en) 2013-12-20 2020-06-11 Dana-Farber Cancer Institute, Inc. Combination therapy with neoantigen vaccine
WO2016100975A1 (en) 2014-12-19 2016-06-23 Massachsetts Institute Ot Technology Molecular biomarkers for cancer immunotherapy
US10993997B2 (en) 2014-12-19 2021-05-04 The Broad Institute, Inc. Methods for profiling the t cell repertoire
EP3297660A2 (en) 2015-05-20 2018-03-28 The Broad Institute Inc. Shared neoantigens
WO2017027778A1 (en) 2015-08-13 2017-02-16 Temple University-Of The Commonwealth System Of Higher Education Calcium alginate dosage formulations, and methods of making and using thereof
WO2017083348A1 (en) 2015-11-11 2017-05-18 Celgene Corporation Controlled release oral dosage forms of poorly soluble drugs and uses thereof
WO2017184590A1 (en) 2016-04-18 2017-10-26 The Broad Institute Inc. Improved hla epitope prediction
US11549149B2 (en) 2017-01-24 2023-01-10 The Broad Institute, Inc. Compositions and methods for detecting a mutant variant of a polynucleotide
US11672863B2 (en) * 2017-05-11 2023-06-13 United Therapeutics Corporation Enhanced solubility drug-containing formulations
US20210382068A1 (en) 2018-10-02 2021-12-09 Dana-Farber Cancer Institute, Inc. Hla single allele lines
WO2020131586A2 (en) 2018-12-17 2020-06-25 The Broad Institute, Inc. Methods for identifying neoantigens
CN111184699A (en) * 2020-04-09 2020-05-22 河北大学 Nifedipine controlled release capsule and preparation method thereof
AU2021280261A1 (en) 2020-05-26 2023-01-19 Dionis Therapeutics, Inc. Nucleic acid artificial mini-proteome libraries
EP4426829A1 (en) 2021-11-01 2024-09-11 Dana-Farber Cancer Institute, Inc. Biologically selected nucleic acid artificial mini-proteome libraries

Family Cites Families (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4296140A (en) * 1977-03-08 1981-10-20 Tri/Valley Growers Molded gelled pimiento body
GB1566609A (en) * 1977-03-10 1980-05-08 Reckitt & Colmann Prod Ltd Pharmaceutical compositions containing cholestyramine and alginic acid
US4289751A (en) * 1979-06-29 1981-09-15 Merck & Co., Inc. Effervescent enteric-coated formulation of soluble form of erythromycin and therapeutic use thereof
JPS60163823A (en) * 1984-02-03 1985-08-26 Taisho Pharmaceut Co Ltd Oral administration pharmaceutical
EP0188040B1 (en) * 1985-01-11 1991-08-14 Abbott Laboratories Limited Slow release solid preparation
US5498424A (en) * 1994-11-30 1996-03-12 Klein; Ira Method of treating obesity

Similar Documents

Publication Publication Date Title
RU97112089A (en) SOLID PHARMACEUTICAL COMPOSITION WITH REGULATED MEDICINAL RELEASE
RO117501B1 (en) Controlled-release pharmaceutical composition
HUT61989A (en) Process for producing 2-deoxy-2,3-didehydro-n-acetylneuraminic acid derivatives and analogs, as well as pharmaceutical compositions comprising same as active ingredient
DE69629797D1 (en) MATRIX FOR CONTROLLED RELEASE OF MEDICINAL PRODUCTS
DK0991646T3 (en) Itraconazole with improved solubility, method of preparation thereof, and a pharmaceutical composition for oral administration containing
UA41446C2 (en) Use of fumagilol or its derivatives for preparing drugs intended for treating intestinal infection and pharmaceutical composition
NO330196B1 (en) Pharmaceutical composition in fast-dispersing dosage form, as well as preparation thereof and method for using fish gelatine bearing in pharmaceutical composition.
KR950702409A (en) CONTROLLED RELEASE MORPHINE PREPARATION
RO116342B1 (en) Oral liquid pharmaceutical composition
CA2253980A1 (en) Locally administrable, biodegradable and sustained-release pharmaceutical composition for periodontitis and process for preparation thereof
RU96116411A (en) QUICKLY DISPERSABLE READY-FORMED DRUG FORM TRAMADOL OR TRAMADOL SALT
WO2002017885A3 (en) Controlled release formulation of erythromycin or a derivative thereof
AU1531199A (en) Pharmaceutical suspension tablet compositions
SI20108B (en) A controlled release formulation for poorly soluble basic drugs
DE60022230D1 (en) PROCESS FOR THE PREPARATION OF CLARITHROMYCIN POLYMORPHEN AND POLYMORPH IV
CA2234426A1 (en) Antibacterial composition for oral administration
PL295329A1 (en) Method of improving oral administration applicability of a biological medication substance: dideoxypurin nucleoside
CA2157323A1 (en) Gepirone dosage form
CA2423783A1 (en) Inhibition of systemic infections in humans and vertebrates by dietary fibers
FR2650503B1 (en) PHARMACEUTICAL COMPOSITION FOR ORAL ADMINISTRATION CONTAINING N-ACETYL-CYSTEINE AND ITS APPLICATION
CA2383212A1 (en) Controlled release oral dosage suitable for oral administration
RU2001128233A (en) A method of manufacturing pharmaceutical dosage forms and their precursors and pharmaceutical dosage form
RU2000119753A (en) SYNTHETIC POLYSACCHARIDES, METHOD FOR PRODUCING THERE AND THEIR PHARMACEUTICAL COMPOSITIONS
PL327323A1 (en) Orally administered 5-asa containing pharmaceutic composition of modified active substance release and method of treating intestinal diseases
RU2000119750A (en) NEW PENTACCHARIDES, METHODS OF THEIR PRODUCTION AND CONTAINING THEIR PHARMACEUTICAL COMPOSITIONS